β2 adrenergic receptor gene polymorphism and coronary atherosclerotic heart disease
10.3969/j.issn.1005-1678.2017.05.137
- VernacularTitle:β2肾上腺素能受体基因多态性与冠状动脉粥样硬化性心脏病相关性
- Author:
Qizeng WANG
;
Shudong XIA
;
Jianzhi SHAO
;
Lin ZHENG
;
Chenrong FAN
- Keywords:
coronary atherosclerotic heart disease;
β2-adrenergic receptor gene;
gene polymorphism;
correlation
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):406-407,410
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the association between β2-adrenergic receptor gene polymorphism and coronary atherosclerotic heart disease, and to provide reference for clinical disease prevention and treatment.MethodsThe clinical data of 200 patients with coronary atherosclerotic heart disease confirmed by coronary angiography were selected and included in the study group, and 200 healthy subjects without coronary atherosclerotic heart disease group.The polymorphism of β2 adrenergic receptor gene was detected and the frequency of each gene was analyzed.ResultsThe genotype frequencies of β2-adrenergic receptor gene were in accordance with Hardy-Weinberg equilibrium, the difference was not statistically significant.According to dominant genetic model, the frequency of AA+AG was 46.0% vs 58.0% lower than that of the control group, and had statistical significance, The genotype frequency of GG genotype in study group was significantly lower than that in control group 14.0% vs 26.0%, χ2=26.20, P=0.00.The frequency of GG genotype in study group was significantly higher than that in control group 54.0% vs 42.0%, χ2=5.76, P=0.01.The frequency of A gene was 38.0% compared with 44.0% in control group, χ2=1.48, P=0.22;the frequency of AA gene in study group was 30.0%, and the frequency of gene A was 38.0%, compared with 56.0% Compared with 32.0% in the control group, χ2=0.18, P=0.66.ConclusionThe A/G polymorphism of β2-adrenergic receptor gene is closely related to the clinical pathogenesis of coronary atherosclerotic heart disease, and the A allele may be a protective factor in patients with coronary atherosclerotic heart disease.
